Cyient is grappling with multiple challenges, including disappointing Q3 results, a downward revision in FY25 growth guidance, and the CEO's resignation, all of which have dampened investor sentiment.
On July 11, It Begins. Superman - Only in Theaters 2025. Traveling over our heads at hypersonic speeds beyond Mach 7, lies the future of spy plane technology. It can be anywhere in the world in one ...
Dr. Reddy's Laboratories shares in Friday's trade slipped by over 6 per cent in early trade to the day's low price of Rs 1,203.6 after the pharma major posted weak performance during the December ...
While National Insurance, United India Insurance and Oriental India Insurance are considered weak, market leader New India Assurance is seen as strong and not a candidate for privatization.
We are bullish on Lynas despite recent underperformance, citing upcoming production increases and potential price benefits. Read more on LYSDY stock here.
Icade offers a high-dividend yield and low valuation, but its weak fundamentals and challenging business prospects justify this profile. Learn more CDMGF stock here.